In geriatric patients

Aniracetam (6), launched in 1993 in both Japan and Italy for the treatment of cognition disorders, is in Phase II trials in the United States as of this writing. In clinical studies it has been shown to cause some improvement in elderly patients with mild to moderate mental deterioration (63), and in geriatric patients with cerebral insufficiency (64). In a multicenter double-blind placebo-controUed trial involving 109 patients with probable AD, positive effects were observed in 36% of patients after six months of treatment (65), a result repeated in a separate study of 115 patients (66). A review of the biological and pharmacokinetic properties, and clinical results of aniracetam treatment in cognitively impaired individuals is available (49). 

The fluoroquinolones are used cautiously in patients with renal impairment or a history of seizures, in geriatric patients, and in patients on dialysis. 

Tolonen, M., Halme, M. and Sama, S. (1985). Vitamin E and selenium supplementation in geriatric patients. A doubleblind preliminary clinical trial. Biol. Trace Element Res. 7, 161-168. 

Horne R and Weinman J (1999) Patients beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 47(6) 555-567 Kannisto V, Lauritsen J, Thatcher AR et al. (1994) Reductions in mortality at advanced age several decades of evidence from 27 countries. Population and development review 20(4) 793-810 Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients a meta- analysis of prospective studies. JAMA 279(15) 1200-1205 LeSage J (1991) Polypharmacy in geriatric patients. Nurs Clin North Am 26(2) 273-290 Pitkala KH, Strandberg TE, Tilvis RS (2001) Is it possible to reduce polypharmacy in the elderly ... 

Before the arrival of the new antidepressants, the older tricyclic antidepressants were widely used to treat depression and agitation in demented patients. They have now largely been abandoned in these patients as their prominent anticholinergic effects tend to worsen dementia and the increased risk for cardiac toxicity can be especially dangerous in geriatric patients. 

Eideriy Dosage reduction may be required in geriatric patients, depending on the underlying renal status of the patient. 

ET OBRA regulated in U.S. Long Term Care Other Uses in Geriatric Patient None Side Effects ... 

Other Uses in Geriatric Patient Anxiety disorders, sleep disorders, seizure disorders... 

Other Uses in Geriatric Patient Behavior disturbances in the setting of dementia... 

Other Uses in Geriatric Patient Treatment of antipsychotic-induced adverse effects... 

Other Uses in Geriatric Patient Bipolar Disorder, PTSD, Alcohol Withrawal, Neuropathic Pain... 

Other Uses in Geriatric Patient Acute allergic reactions, urticaria (in addition to antihistamine therapy)... 

---